News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Acambis PLC Announces Research Update
November 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Acambis plc's (" Acambis") (LSE: ACM, NASDAQ: ACAM) programme to develop a second-generation, single-dose vaccine against Japanese encephalitis ("JE") has achieved a major milestone with the start of pivotal Phase III trials.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
Career Advice
Going With the Flow: Finding Success in Academic and Biotech Research Cultures
January 21, 2026
·
6 min read
·
Manali Shah
Cancer
Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo
January 20, 2026
·
2 min read
·
Annalee Armstrong
Lymphoma
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
January 19, 2026
·
2 min read
·
Tristan Manalac
